Investigating the Accuracy of the openFDA API using the FDA Adverse Event Reporting System (FAERS)

被引:0
|
作者
Shin, Jennifer [1 ]
机构
[1] 8 Path Solut LLC, New York, NY 10024 USA
来源
2014 IEEE INTERNATIONAL CONFERENCE ON BIG DATA (BIG DATA) | 2014年
关键词
openFDA; FDA; adverse events; FDA Adverse Events Reporting System; FAERS; SURVEILLANCE;
D O I
暂无
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) is a database that contains information on adverse event and medication error reports submitted to the FDA. Each quarter the FDA releases the data to the public, but accessing the data requires researchers to download, import, and consolidate data for every quarter starting from 2004. In an effort to provide easier access to this, the FDA launched the openFDA initiative in June 2014, which gives the public API access to information about adverse events reports. Although the API enables easier access to the FAERS data, the quality of the API design and the features of the data set will determine the reliability of the information retrieved. Thus, errors in the API can result in inaccurate and unreliable data analysis. Furthermore, the number of adverse events reports retrieved by the API for a particular drug can differ from the FAERS data files due to the openFDA harmonization process and the existence of multiple entries and variations for any given drug name in the FAERS data files. Since there are no universal rule that can be used to identify errors or potential issues, we propose evaluating the openFDA API by searching for a particular drug (brand name), Yaz, and the generic name, Drospirenone Ethinyl Estradiol, and comparing the results against the FAERS data files. Our results show that in the case of Yaz, the openFDA API and the drug harmonization process is inaccurate and inconsistent.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Adverse events analysis of Relugolix (Orgovyx®) for prostate cancer based on the FDA Adverse Event Reporting System (FAERS)
    Li, Ruibo
    Chen, Xi
    Wang, Yujie
    PLOS ONE, 2024, 19 (10):
  • [42] Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
    Li, Ruibo
    Yuan, Xingyue
    Chen, Xi
    Ou, Yili
    Chen, Jin
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [43] Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023
    Liu, Luyu
    Wu, Shaobo
    Wei, Liangliang
    Xia, Zhihao
    Ji, Jiajia
    Huang, Dageng
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2025, 37 (01)
  • [44] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [45] Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
    Li, Yun
    Li, Hang
    Xiang, Zhongyuan
    HELIYON, 2024, 10 (06)
  • [46] Pharmacovigilance analysis of peripheral neuropathy with newer generation proteasome inhibitors: Using the FDA Adverse Event Reporting System (FAERS)
    Mina, S. A.
    Muhsen, I. N.
    Burns, E. A.
    Sarfaraz, H.
    Xu, J.
    Hashmi, S. K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 121 - 121
  • [47] A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS)
    Kate E. Rees
    Te-yuan Chyou
    Prasad S. Nishtala
    Drug Safety, 2020, 43 : 607 - 609
  • [48] Neuropsychiatric adverse events of chloroquine: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
    Sato, Kenichiro
    Mano, Tatsuo
    Iwata, Atsushi
    Toda, Tatsushi
    BIOSCIENCE TRENDS, 2020, 14 (02) : 139 - 143
  • [49] Ocrelizumab-related neutropenia: effects of age, sex and bodyweight using the FDA adverse event reporting system (FAERS)
    Hammer, H.
    Kamber, N.
    Pistor, M.
    Diem, L.
    Friedli, C.
    Chan, A.
    Hoepner, R.
    Salmen, A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 636 - 636
  • [50] Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS)
    Hammer, H.
    Kamber, N.
    Pistor, M.
    Diem, L.
    Friedli, C.
    Chan, A.
    Hoepner, R.
    Salmen, A.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 65